<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03402399</url>
  </required_header>
  <id_info>
    <org_study_id>0124-17</org_study_id>
    <nct_id>NCT03402399</nct_id>
  </id_info>
  <brief_title>Defining the Molecular Risk in Israeli Patients With Secondary Compared to Primary Myelofibrosis</brief_title>
  <acronym>MRMF01</acronym>
  <official_title>Defining the Molecular Risk in Israeli Patients With Secondary Compared to Primary Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine the rate of HMR mutations in PMF and secondary MF (post
      PV/ET) subjects, and correlate the rate of mutations with clinical features as known
      prognostic scores.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main inclusion criteria:

        1. Diagnosis of PMF, post PV MF or post ET MF according to the WHO 2008 classification

        2. Age â‰¥ 18 years

        3. Concurrent participation in clinical trials will be allowed.

      Efficacy assessments will be evaluated by: HMR mutations rate, specific HMR mutations,
      disease duration, presence of splenomegaly, cytogenetic risk, DIPPS, IPSS, ET survival score
      and PV survival score.

      The primary efficacy parameter to be assessed will be HMR mutation rate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2017</start_date>
  <completion_date type="Anticipated">December 9, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 9, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients with one or more HMR mutations in primary compared to secondary (post PV/ET) MF</measure>
    <time_frame>Baseline</time_frame>
    <description>Proportions of patients with HMR mutations in each arm</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">222</enrollment>
  <condition>Myelofibrosis, Primary</condition>
  <condition>Myelofibrosis, Post PV</condition>
  <condition>Myelofibrosis, Post ET</condition>
  <arm_group>
    <arm_group_label>Primary Myelofibrosis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Secondary Myelofibrosis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood test</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Molecular analysis</intervention_name>
    <description>Blood test</description>
    <arm_group_label>Primary Myelofibrosis</arm_group_label>
    <arm_group_label>Secondary Myelofibrosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of PMF, post PV MF or post ET MF according to the WHO 2008 classification

          2. Age . 18 years

          3. Patient is willing and capable of giving a written informed consent.

          4. Concurrent participation in clinical trials will be allowed

        Exclusion Criteria:

          1. Unwilling or unable to provide informed consent

          2. Prefibrotic MF
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maya Koren-Michowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assaf-Harofeh Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shirly Broitman</last_name>
    <phone>+972-8-9778452</phone>
    <email>shirlib@asaf.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Center</name>
      <address>
        <city>Zerifin</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maya Koren-Michowitz, MD</last_name>
      <email>korenm@asaf.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2018</study_first_submitted>
  <study_first_submitted_qc>January 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2018</study_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

